These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 32796282)

  • 1. Current trends in the clinical trial landscape for amyotrophic lateral sclerosis.
    van Eijk RPA; Kliest T; van den Berg LH
    Curr Opin Neurol; 2020 Oct; 33(5):655-661. PubMed ID: 32796282
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical trials in amyotrophic lateral sclerosis.
    McDermott CJ
    Curr Opin Neurol; 2019 Oct; 32(5):758-763. PubMed ID: 31335338
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TRICALS: creating a highway toward a cure.
    van Eijk RPA; Kliest T; McDermott CJ; Roes KCB; Van Damme P; Chio A; Weber M; Ingre C; Corcia P; Povedano M; Reviers E; van Es MA; Al-Chalabi A; Hardiman O; van den Berg LH
    Amyotroph Lateral Scler Frontotemporal Degener; 2020 Nov; 21(7-8):496-501. PubMed ID: 32643415
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Amyotrophic lateral sclerosis: lessons in trial design from recent trials.
    Borasio GD
    J Neurol Sci; 1997 Oct; 152 Suppl 1():S23-8. PubMed ID: 9419050
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Considerations for Amyotrophic Lateral Sclerosis (ALS) Clinical Trial Design.
    Fournier CN
    Neurotherapeutics; 2022 Jul; 19(4):1180-1192. PubMed ID: 35819713
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND).
    Miller RG; Mitchell JD; Lyon M; Moore DH
    Amyotroph Lateral Scler Other Motor Neuron Disord; 2003 Sep; 4(3):191-206. PubMed ID: 13129806
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Critical design considerations for time-to-event endpoints in amyotrophic lateral sclerosis clinical trials.
    van Eijk RPA; Nikolakopoulos S; Roes KCB; Middelkoop BM; Ferguson TA; Shaw PJ; Leigh PN; Al-Chalabi A; Eijkemans MJC; van den Berg LH
    J Neurol Neurosurg Psychiatry; 2019 Dec; 90(12):1331-1337. PubMed ID: 31292200
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recombinant human insulin-like growth factor I (rhIGF-I) for amyotrophic lateral sclerosis/motor neuron disease.
    Mitchell JD; Wokke JH; Borasio GD
    Cochrane Database Syst Rev; 2002; (3):CD002064. PubMed ID: 12137643
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluating emerging drugs in phase II & III for the treatment of amyotrophic lateral sclerosis.
    Li X; Bedlack R
    Expert Opin Emerg Drugs; 2024 Jun; 29(2):93-102. PubMed ID: 38516735
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recombinant human insulin-like growth factor I (rhIGF-I) for amyotrophic lateral sclerosis/motor neuron disease.
    Mitchell JD; Wokke JH; Borasio GD
    Cochrane Database Syst Rev; 2007 Oct; (4):CD002064. PubMed ID: 17943766
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Induced pluripotent stem cell-based Drug Repurposing for Amyotrophic lateral sclerosis Medicine (iDReAM) study: protocol for a phase I dose escalation study of bosutinib for amyotrophic lateral sclerosis patients.
    Imamura K; Izumi Y; Banno H; Uozumi R; Morita S; Egawa N; Ayaki T; Nagai M; Nishiyama K; Watanabe Y; Hanajima R; Oki R; Fujita K; Takahashi N; Ikeda T; Shimizu A; Morinaga A; Hirohashi T; Fujii Y; Takahashi R; Inoue H
    BMJ Open; 2019 Dec; 9(12):e033131. PubMed ID: 31796494
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The biopharmaceutical industry and new drugs for amyotrophic lateral sclerosis.
    Malta E
    Adv Neurol; 1995; 68():263-9; discussion 271-5. PubMed ID: 8787239
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mecasin treatment in patients with amyotrophic lateral sclerosis: study protocol for a randomized controlled trial.
    Kim S; Kim JK; Son MJ; Kim D; Song B; Son I; Kang HW; Lee J; Kim S
    Trials; 2018 Apr; 19(1):225. PubMed ID: 29653550
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Toward more efficient clinical trials for amyotrophic lateral sclerosis.
    Cudkowicz ME; Katz J; Moore DH; O'Neill G; Glass JD; Mitsumoto H; Appel S; Ravina B; Kieburtz K; Shoulson I; Kaufmann P; Khan J; Simpson E; Shefner J; Levin B; Cwik V; Schoenfeld D; Aggarwal S; McDermott MP; Miller RG
    Amyotroph Lateral Scler; 2010 May; 11(3):259-65. PubMed ID: 19961263
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A placebo arm is not always necessary in clinical trials of amyotrophic lateral sclerosis.
    Gordon PH
    Muscle Nerve; 2009 Jun; 39(6):858-60. PubMed ID: 19382169
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Riluzole and edaravone: A tale of two amyotrophic lateral sclerosis drugs.
    Jaiswal MK
    Med Res Rev; 2019 Mar; 39(2):733-748. PubMed ID: 30101496
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND).
    Miller RG; Mitchell JD; Lyon M; Moore DH
    Cochrane Database Syst Rev; 2002; (2):CD001447. PubMed ID: 12076411
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and efficacy of rasagiline as an add-on therapy to riluzole in patients with amyotrophic lateral sclerosis: a randomised, double-blind, parallel-group, placebo-controlled, phase 2 trial.
    Ludolph AC; Schuster J; Dorst J; Dupuis L; Dreyhaupt J; Weishaupt JH; Kassubek J; Weiland U; Petri S; Meyer T; Grosskreutz J; Schrank B; Boentert M; Emmer A; Hermann A; Zeller D; Prudlo J; Winkler AS; Grehl T; Heneka MT; Wollebæk Johannesen S; Göricke B;
    Lancet Neurol; 2018 Aug; 17(8):681-688. PubMed ID: 29934198
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Study protocol for a randomised, double-blind, placebo-controlled study evaluating the Efficacy of cannabis-based Medicine Extract in slowing the disease pRogression of Amyotrophic Lateral sclerosis or motor neurone Disease: the EMERALD trial.
    Urbi B; Broadley S; Bedlack R; Russo E; Sabet A
    BMJ Open; 2019 Nov; 9(11):e029449. PubMed ID: 31719072
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enhancing clinical trials in neurodegenerative disorders: lessons from amyotrophic lateral sclerosis.
    Gladman M; Cudkowicz M; Zinman L
    Curr Opin Neurol; 2012 Dec; 25(6):735-42. PubMed ID: 23160423
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.